Pancreatic Cancer Research

ResearcherGarvan Institute of Medical ResearchActive in the last 2 years

Marina Pajic

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3871-3829; OpenAlex author ID A5073106472. Sources: OpenAlex.

Their work

Papers
54 (first author 3, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
130
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 2 papers · 2014: 5 papers · 2015: 6 papers · 2016: 2 papers · 2017: 6 papers · 2018: 6 papers · 2019: 2 papers · 2020: 6 papers · 2021: 6 papers · 2022: 2 papers · 2023: none · 2024: 2 papers · 2025: 4 papers · 2026: 2 papers

Papers 50 of 54

  1. βIII-tubulin can act as a brake on extrinsic apoptosis in pancreatic cancer. Co-author DOI 10.1038/s41419-026-08657-6↗
  2. Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer Co-author DOI 10.64898/2026.07.23.740234↗
  3. Oncogenic small extracellular vesicles enriched in sphingosine-1-phosphate play a crucial role in pancreatic cancer progression. Co-author DOI 10.1016/j.cellsig.2025.111775↗
  4. MYH knockdown in pancreatic cancer cells creates an exploitable DNA repair vulnerability. Co-author DOI 10.1016/j.neo.2025.101138↗
  5. Oncogenic proteome of pancreatic cancer extracellular vesicles: sodium/myo-inositol cotransporter as a potential marker. Co-author DOI 10.1038/s41392-025-02232-9↗
  6. Targeting the NPY/NPY1R signaling axis in mutant p53-dependent pancreatic cancer impairs metastasis. Co-author DOI 10.1126/sciadv.adq4416↗
  7. Fibroblast Activation Protein Is Overexpressed on Both Stromal and Epithelial Cells Before Pancreatic Ductal Adenocarcinoma: Implications for Early Diagnosis o… Co-author DOI 10.1053/j.gastro.2024.06.033↗
  8. Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response. Co-author DOI 10.1126/sciadv.adl1197↗
  9. Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. Co-author DOI 10.1053/j.gastro.2021.09.022↗
  10. βIII-Tubulin is a Brake on Extrinsic Cell-Death in Pancreatic Cancer Co-author DOI 10.1101/2022.09.29.510034↗
  11. TLR2 activation promotes tumour growth and associates with patient survival and chemotherapy response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-021-01992-2↗
  12. Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2020.09.043↗
  13. Breaking the cycle: Targeting of NDRG1 to inhibit bi-directional oncogenic cross-talk between pancreatic cancer and stroma. Co-author DOI 10.1096/fj.202002279r↗
  14. Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status. Co-author DOI 10.1126/sciadv.abh0363↗
  15. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition. Co-author DOI 10.1158/0008-5472.can-20-2496↗
  16. ROR1 and ROR2 expression in pancreatic cancer. Co-author DOI 10.1186/s12885-021-08952-9↗
  17. HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. Co-author DOI 10.1016/j.celrep.2020.107625↗
  18. MCL-1 antagonism enhances the anti-invasive effects of dasatinib in pancreatic adenocarcinoma. Co-author DOI 10.1038/s41388-019-1091-0↗
  19. Targeting ROCK activity to disrupt and prime pancreatic cancer for chemotherapy. Co-author DOI 10.1080/21541248.2017.1345712↗
  20. Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003143↗
  21. Fats and Mets, KRAS-Driven Lipid Dysregulation Affects Metastatic Potential in Pancreatic Cancer. First author DOI 10.1158/0008-5472.can-20-3082↗
  22. Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.7150/thno.43589↗
  23. Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy. Last author DOI 10.1111/febs.15011↗
  24. PAK inhibition by PF-3758309 enhanced the sensitivity of multiple chemotherapeutic reagents in patient-derived pancreatic cancer cell lines. Co-author PMID 31312349↗
  25. Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer. Co-author DOI 10.1016/j.celrep.2018.05.038↗
  26. Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2017.11.280↗
  27. Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Last author DOI 10.1136/gutjnl-2017-315144↗
  28. Rho Kinase Inhibition by AT13148 Blocks Pancreatic Ductal Adenocarcinoma Invasion and Tumor Growth. Co-author DOI 10.1158/0008-5472.can-17-1339↗
  29. The PAK Inhibitor PF-3758309 Promotes the Inhibitory Effects of Multiple Chemotherapeutic Reagents on Patient-Derived Pancreatic Cancer Cell Lines Co-author DOI 10.20944/preprints201809.0322.v1↗
  30. The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/diseases6040103↗
  31. SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer. Co-author DOI 10.1038/onc.2017.63↗
  32. Hypermutation In Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2016.09.060↗
  33. Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Co-author DOI 10.1126/scitranslmed.aai8504↗
  34. GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2015-311256↗
  35. Mitochondrial mutations and metabolic adaptation in pancreatic cancer. Co-author DOI 10.1186/s40170-017-0164-1↗
  36. Transient targeting of the pancreatic cancer stroma as a 'fine-tuned' anti-tumor and anti-metastatic therapy. Co-author DOI 10.18632/oncotarget.21468↗
  37. Genomic analyses identify molecular subtypes of pancreatic cancer. Co-author DOI 10.1038/nature16965↗
  38. Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling. Co-author DOI 10.1074/mcp.m116.058313↗
  39. Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials. Co-author DOI 10.1016/j.critrevonc.2015.07.007↗
  40. Imaging fibrosis in pancreatic cancer using second harmonic generation. First author DOI 10.1016/j.pan.2015.02.004↗
  41. Whole genomes redefine the mutational landscape of pancreatic cancer. Co-author DOI 10.1038/nature14169↗
  42. SOX9 regulates ERBB signalling in pancreatic cancer development. Co-author DOI 10.1136/gutjnl-2014-307075↗
  43. Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. Co-author DOI 10.1158/1078-0432.ccr-15-0426↗
  44. The epigenetic agents suberoylanilide hydroxamic acid and 5‑AZA‑2' deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa… Co-author DOI 10.3892/ijo.2015.2894↗
  45. Clinical and pathologic features of familial pancreatic cancer. Co-author DOI 10.1002/cncr.28863↗
  46. Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. Co-author DOI 10.1002/ijc.28765↗
  47. Adjuvant chemotherapy in elderly patients with pancreatic cancer. Co-author DOI 10.1038/bjc.2013.722↗
  48. Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma. First author DOI 10.1158/1078-0432.ccr-14-0048↗
  49. Returning individual research results for genome sequences of pancreatic cancer. Co-author DOI 10.1186/gm558↗
  50. Understanding pancreatic cancer genomes. Co-author DOI 10.1007/s00534-013-0610-6↗

Closest collaborators

The 25 strongest of 130 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anthony James Gill · 16 shared papers, 2012–2026 · strength 1.25
  2. Paul Timpson · 13 shared papers, 2015–2021 · strength 1.13
  3. Amber L. Johns · 16 shared papers, 2012–2026 · strength 1.12
  4. Andrew Victor Biankin · 20 shared papers, 2011–2021 · strength 0.87
  5. Claire Vennin · 9 shared papers, 2015–2021 · strength 0.74
  6. Jennifer P. Morton · 8 shared papers, 2017–2026 · strength 0.73
  7. Ashleigh Parkin · 8 shared papers, 2018–2021 · strength 0.70
  8. Jaswinder Singh Samra · 11 shared papers, 2012–2024 · strength 0.64
  9. David Goldstein · 5 shared papers, 2013–2026 · strength 0.60
  10. Jennifer Man · 5 shared papers, 2018–2020 · strength 0.59
  11. Angela S. Y. Chou · 10 shared papers, 2013–2021 · strength 0.59
  12. Joshua A. McCarroll · 4 shared papers, 2021–2026 · strength 0.58
  13. Mert Erkan · 4 shared papers, 2021–2026 · strength 0.58
  14. Koroush Shahsavar Haghighi · 4 shared papers, 2021–2026 · strength 0.58
  15. Phoebe A. Phillips · 4 shared papers, 2021–2026 · strength 0.58
  16. George Sharbeen · 4 shared papers, 2021–2026 · strength 0.58
  17. John Kokkinos · 4 shared papers, 2021–2026 · strength 0.58
  18. Marco Falasca · 2 shared papers, 2025 · strength 0.57
  19. Adnan M. Nagrial · 11 shared papers, 2012–2020 · strength 0.51
  20. David Kuang-Fu Chang · 13 shared papers, 2011–2020 · strength 0.50
  21. Australian Pancreatic Cancer Genome Initiative · 4 shared papers, 2014–2026 · strength 0.47
  22. Sean Michael Grimmond · 11 shared papers, 2013–2021 · strength 0.46
  23. Thomas R. Cox · 5 shared papers, 2017–2021 · strength 0.41
  24. Mark J. Cowley · 9 shared papers, 2013–2020 · strength 0.40
  25. Val Gebski · 3 shared papers, 2021–2026 · strength 0.39

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.